← All trials
NCT05815927
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2024
- Primary completion
- Nov 1, 2026
- Completion date
- Sep 1, 2029
- First posted
- Apr 18, 2023
- Last posted
- May 24, 2023
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- European Organisation for Research and Treatment of CancerLead sponsor
- MerckCollaborator
- Swiss Group for Clinical Cancer ResearchCollaborator
- University of ZurichStudy chair
- University of ZurichOfficial
- Swiss Cancer InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.